Naoki Akagi
Papers
1
Total Citations
4
H-Index
1
About
Naoki Akagi is a urologic oncologist whose research centers on optimizing treatment strategies for high-risk prostate cancer, particularly through neoadjuvant chemohormonal therapy and robotic-assisted surgery. His most cited work investigates the critical role of dose compliance with estramustine phosphate when combined with degarelix acetate prior to robot-assisted radical prostatectomy. In a study of 187 patients with very high-risk disease, Akagi demonstrated that strict adherence to this neoadjuvant regimen significantly predicts biochemical recurrence-free survival, offering a practical biomarker for treatment success. This finding directly addresses a major clinical challenge: identifying which patients will benefit most from intensive preoperative therapy. By linking medication compliance to oncologic outcomes, his research provides actionable insights for personalizing care in aggressive prostate cancer. Akagi’s work bridges surgical oncology and pharmacotherapy, contributing to the growing evidence base for multimodal management of high-risk disease. His findings carry implications for both clinical trial design and real-world treatment protocols, helping to refine the balance between efficacy and tolerability in neoadjuvant settings.
Research Focus
Key Achievements
Top Papers
- 1